PHIN-214 not checked

PharmaIN

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“subcutaneous injection(s) with PHIN-214 terlipressin derivative”In the company’s words, NCT05490888 on ClinicalTrials.gov
Tested for
Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Main trialPhase 1
“This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.”In the company’s words, NCT05490888 on ClinicalTrials.gov
Other names
Terlipressin derivative

Other drugs for Cirrhosis, Liver

All 19 drugs for Cirrhosis, Liver

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 May 2026 Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PHIN-214

Following is part of Solo: you see every change to PHIN-214 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in